Targeting-intratumoral-lactic-acidosis transcatheter-arterial-chemoembolization for non-islet cell tumor hypoglycemia secondary to a liver metastatic solitary fibrous tumor: A case report and literature review

Jin, Kai; Zhong, Shengwen; Lin, Li; Wu, Jianjun; Wang, Yuqi; Cui, Weijuan; Gu, Wanyi; Chao, M.; Song, Xiaoxiao

doi:10.3389/fendo.2022.955687

Cited by 8 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sunitinib, another tyrosine kinase inhibitor was used to treat 31 patients and reportedly achieved 6% RECIST PR and 52% SD (12). Recently, a case report described the benefit of targeting intratumoral lactic acidosis TACE for non-islet cell tumor hypoglycemia secondary to hepatic metastasis of SFT (13). Therefore, improved chemotherapeutic agents and endovascular therapies, such as TACE, may have a synergistic effect, and further studies are needed to elucidate their precise role.…”

Section: Discussionmentioning

confidence: 99%

Transarterial Chemoembolization for Hepatic Metastasis of Solitary Fibrous Tumor

Kwon,

Choi,

Kim

2023

Iran J Radiol

View full text Add to dashboard Cite

Introduction: Solitary fibrous tumors (SFT) are rare soft tissue tumors with a typically benign clinical course; however, up to 35% of SFT exhibit metastasis, resulting in a poor prognosis. The management of hepatic metastasis of SFT is yet to be established because of its rarity of cases. Objectives: Herein, we report the clinical results of 13 TACE sessions for hepatic metastasis in 5 patients with SFT. Patients and Methods: Patients with hepatic metastases from SFT who underwent TACE between May 2005 and April 2021 were retrospectively reviewed. Tumor response was evaluated using the modified response evaluation criteria in solid tumors (mRECIST). Results: Five patients (one male, mean age: 59.2 years) underwent 13 TACE sessions, resulting in four partial responses (PR, 30.8%), four stable disease cases (30.8%), and five progressive disease cases (38.5%). No severe complications occurred. Four of seven sessions (57.1%) of selective TACE showed PR. The mean progression-free survival (PFS) was 2.3 months (range: 0 - 8 months), and for sessions with PR, the mean PFS was 6.3 months (range: 3 - 8 months). The mean overall survival was 32.7 months (range: 18 - 44 months). Conclusions: This report suggests that TACE might be a potentially safe treatment option for hepatic metastasis of SFT, and it could offer a benefit in controlling local tumor growth in cases where selective TACE is applicable.

show abstract

Section: Discussionmentioning

confidence: 99%

Transarterial Chemoembolization for Hepatic Metastasis of Solitary Fibrous Tumor

Kwon,

Choi,

Kim

2023

Iran J Radiol

View full text Add to dashboard Cite

show abstract

“…Complete resection or tumor debulking of the Big‐IGF‐II producing SFT is the most promising treatment for patients with DPS, particularly in light of the fact that the majority of metabolic alterations due to increased Big‐IGF‐II are fully reversible 10,12,17 . Adjuvant chemotherapy and radiotherapy might also improve the general outcome 18,19 . Apart from surgery, glucocorticoids may be considered for long‐term therapy, as they appear to suppress secretion of Big‐IGF‐II and may contribute a protective effect for hypoglycemia by increasing insulin resistance 3 .…”

Section: Introductionmentioning

confidence: 99%

“… 10 , 12 , 17 Adjuvant chemotherapy and radiotherapy might also improve the general outcome. 18 , 19 Apart from surgery, glucocorticoids may be considered for long‐term therapy, as they appear to suppress secretion of Big‐IGF‐II and may contribute a protective effect for hypoglycemia by increasing insulin resistance. 3 Despite variable expression of somatostatin receptors (SSTR) in SFT, Octreotide has so far been reported to be ineffective in treatment of DPS.…”

Section: Introductionmentioning

confidence: 99%

Effective management of recurrent Doege–Potter syndrome with somatostatin‐analogues: A case report

Schöler,

Storz,

Khavaran

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundDoege–Potter syndrome is defined as paraneoplastic hypoinsulinemic hypoglycemia associated with a benign or malignant solitary fibrous tumor frequently located in pleural, but also extrapleural sites. Hypoglycemia can be attributed to paraneoplastic secretion of “Big‐IGF‐II,” a precursor of Insulin‐like growth factor‐II. This prohormone aberrantly binds to and activates insulin receptors, with consecutive initiation of common insulin actions such as inhibition of gluconeogenesis, activation of glycolysis and stimulation of cellular glucose uptake culminating in recurrent tumor‐induced hypoglycemic episodes. Complete tumor resection or debulking surgery is considered the most promising treatment for DPS.CaseHere, we report a rare case of a recurrent Doege‐Poter Syndrome with atypical gelatinous tumor lesions of the lung, pleura and pericardial fat tissue in an 87‐year‐old woman. Although previously described as ineffective, we propose that adjuvant treatment with Octreotide in conjunction with intravenous glucose helped to maintain tolerable blood glucose levels before tumor resection. The somatostatin‐analogue Lanreotide was successfully used after tumor debulking surgery (R2‐resection) to maintain adequate blood glucose control.ConclusionWe conclude that somatostatin‐analogues bear the potential of being effective in conjunction with limited surgical approaches for the treatment of hypoglycemia in recurrent or non‐totally resectable SFT entities underlying DPS.

show abstract

“…The objective response rate (ORR) was 100% when sodium bicarbonate was employed, while the rate was 44.4% with conventional TACE in a nonrandomized cohort, and 63.6% in a randomized study ( 14 ). A recent case study reported that a 46-year-old man with Doege-Potter syndrome, secondary to liver and pancreatic metastatic solitary fibrous tumors, achieved clinical cure of hypoglycemia and well-controlled liver metastatic tumor after receiving six rounds of TILA-TACE treatment ( 15 ). These findings suggest that sodium bicarbonate solution may have potential therapeutic benefits for cancer treatment, although further studies are needed to confirm these results.…”

Section: Introductionmentioning

confidence: 99%

Tumor alkalization therapy: misconception or good therapeutics perspective? – the case of malignant ascites

Bogdanov,

Verlov,

Bogdanov

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Tumor acidity has been identified as a key factor in promoting cancer progression, metastasis, and resistance. Tumor alkalization therapy has emerged as a potential strategy for cancer treatment. This article provides preclinical and clinical evidence for tumor alkalization therapy as a promising cancer treatment strategy. The potential of tumor alkalization therapy using sodium bicarbonate in the treatment of malignant ascites was studied. The concept of intraperitoneal perfusion with an alkalizing solution to increase the extracellular pH and its antitumor effect were explored. The significant extension in the overall survival of the Ehrlich ascites carcinoma mice treated with sodium bicarbonate solution compared to those treated with a sodium chloride solution was observed. In the sodium bicarbonate group, mice had a median survival of 30 days after tumor cell injection, which was significantly (p<0.05) different from the median survival of 18 days in the sodium chloride group and 14 days in the intact group. We also performed a case study of a patient with ovarian cancer malignant ascites resistant to previous lines of chemotherapy who underwent intraperitoneal perfusions with a sodium bicarbonate solution, resulting in a significant drop of CA-125 levels from 5600 U/mL to 2200 U/mL in and disappearance of ascites, indicating the potential effectiveness of the treatment. The preclinical and clinical results obtained using sodium bicarbonate perfusion in the treatment of malignant ascites represent a small yet significant contribution to the evolving field of tumor alkalization as a cancer therapy. They unequivocally affirm the good prospects of this concept.

show abstract

Targeting-intratumoral-lactic-acidosis transcatheter-arterial-chemoembolization for non-islet cell tumor hypoglycemia secondary to a liver metastatic solitary fibrous tumor: A case report and literature review

Cited by 8 publications

References 44 publications

Transarterial Chemoembolization for Hepatic Metastasis of Solitary Fibrous Tumor

Transarterial Chemoembolization for Hepatic Metastasis of Solitary Fibrous Tumor

Effective management of recurrent Doege–Potter syndrome with somatostatin‐analogues: A case report

Tumor alkalization therapy: misconception or good therapeutics perspective? – the case of malignant ascites

Contact Info

Product

Resources

About